Related Experiment Videos
Prostate specific antigen: an opinion on its value to the radiologist
1Department of Radiology, Royal Gwent Hospital, Cardiff Road, Newport NP9 2UB, S. Wales, UK.
European Radiology
|March 23, 1999
Summary
Prostate cancer screening is debated due to unproven mortality reduction. Prostate-specific antigen (PSA) aids diagnosis but lacks specificity, prompting research into improved screening methods for early prostate cancer detection.
Area of Science:
- Urology
- Radiology
- Biochemistry
Background:
- Prostate cancer screening faces public and media pressure, mirroring breast cancer screening.
- Unlike breast cancer screening, prostate cancer screening has not yet demonstrated a reduction in mortality.
- Prostate-specific antigen (PSA) is the primary diagnostic marker but cannot distinguish between indolent and aggressive disease.
Purpose of the Study:
- To review current knowledge of prostate-specific antigen (PSA) from a radiologist's perspective.
- To discuss the challenges and advancements in improving PSA specificity for prostate cancer diagnosis.
- To provide clarity for clinicians regarding novel diagnostic approaches.
Main Methods:
- Review of existing literature on prostate-specific antigen (PSA) and its role in prostate cancer diagnosis.
- Analysis of current and emerging methods to enhance PSA specificity.
- Radiological viewpoint on diagnostic aids and their interpretation.
Main Results:
- PSA has significantly improved the detection of organ-confined prostate cancer.
- PSA remains an imperfect marker, necessitating further investigation for improved specificity.
- Various new approaches are being explored to refine prostate cancer diagnosis.
Conclusions:
- Prostate cancer screening remains controversial, with ongoing efforts to improve diagnostic accuracy.
- Enhanced specificity of PSA testing is crucial for effective prostate cancer management.
- Radiologists play a key role in interpreting advanced diagnostic tools for prostate cancer.